An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. (2019)
Attributed to:
MICA: The role of Src in cancer-induced bone pain
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jbo.2019.100261
PubMed Identifier: 31667062
Publication URI: http://europepmc.org/abstract/MED/31667062
Type: Journal Article/Review
Volume: 19
Parent Publication: Journal of bone oncology
ISSN: 2212-1366